Protein that helps predict prostate cancer survival identifiedApril 23rd, 2008 - 1:48 pm ICT by admin
Washington, Apr 23 (ANI): A researcher at the Oregon Health & Science University Cancer Institute has identified a protein that is a strong indicator of survival for men with advanced prostate cancer.
The C-reactive protein, also known as CRP, is a special type of protein produced by the liver that is elevated in the presence of inflammation.
“This could mean that a simple blood test that is already available could help in clinical decision making and patient counseling. Patients and doctors would know better what to expect from the prostate cancer they are facing,” said Tomasz Beer, M.D., director of the Prostate Cancer Research Program at the OHSU Cancer Institute, associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.
Past research has shown that cancer causes an inflammatory response.
The research also suggests that inflammation may play an important role in driving prostate cancer progression and resistance to therapy.
Inflammatory cells are attracted to cancer sites and this local inflammation can lead to a release of inflammatory markers, like CRP.
“While inflammation may sometimes slow the progression of the cancer, an increasing body of evidence suggests that cancer can actually take advantage of the inflammatory response, and the reaction of the immune system may fuel cancer progression. To the extent that our hypothesis proves true, C-reactive protein may be reflecting the overall intensity of the inflammation,” Beer said.
The finding that higher CRP is associated with shorter survival and a lower probability of response to chemotherapy is a result of a secondary analysis of inflammatory markers in patients enrolled in the ASCENT study, a large Phase 2 clinical trial that evaluated treatment with docetaxel and DN-101, a high dose formulation of calcitriol or docetaxel with placebo.
This analysis included patients from both groups.
Because this is the first time CRP has been linked with both response and survival in study subjects with advanced prostate cancer receiving chemotherapy, it will be important to confirm this finding in an independent data set before this can become a routine blood test for men with advanced prostate cancer, Beer explained.
If confirmed, besides providing useful information for the patient, this finding could also provide us with vital insight into the fundamental role of inflammation in the progression of advanced prostate cancer. A better understanding of this process could provide us with novel therapeutic interventions for control of this disease and its symptoms, Beer said.
The study is published online in the journal Cancer. (ANI)
- Blood test for inflammation could also show risk for colon cancer - Apr 20, 2010
- Study examines aspirin's ability to protect against colorectal cancer - Mar 10, 2011
- Chronic brain inflammation 'linked to memory loss in older adults' - Apr 14, 2011
- Inflammation drug promising in depression - Sep 04, 2012
- Potent anticancer drug isolated from weed - Jul 10, 2012
- Dormant virus might make you diabetic - Aug 28, 2012
- New drug hope for lung cancer sufferers - Mar 29, 2011
- Chemo-Vandetanib combo effective for lung cancer treatment: Study - Jun 06, 2010
- Mangosteen juice may help prevent heart disease, diabetes in the obese - Nov 03, 2009
- Poor sleep ups risk of heart disease, stroke: Study - Nov 15, 2010
- Targeted cancer drug more effective after first-line treatment - Feb 28, 2011
- Cuba launches world's first lung cancer retardant - Sep 07, 2011
- Early warning signs for prostate cancer identified - Nov 07, 2010
- Chemo-radiation combo may avert prostate cancer recurrence - Nov 05, 2009
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010